• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory

    Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies

    Waters Corp. Acquires Light Scattering Company Wyatt Technology
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    How CDMOs Can Leverage Contract Terms to Facilitate Payment

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory

    Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Traceability & 2D Barcodes

    Complex in Complex – New Hopes for Better Drug Delivery in Topical Dosage Formulation

    Proactive Resource Group Offers DSCSA Services for Pharma Companies

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    TraceLink, PharmaLink Partner to Simplify DSCSA Compliance
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    How CDMOs Can Leverage Contract Terms to Facilitate Payment

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory

    Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?

    FDA Watch: Is Your Supply Chain at Risk?

    FDA Watch: CDER to Launch Guidance Snapshot Pilot Program

    "3 Key Trends" with Paul Josephs
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Almac Group

    LOTTE BIOLOGICS

    U.S. Pharmacopeia (USP)

    INCOG BioPharma Services

    Societal CDMO
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    LOTTE BIOLOGICS

    U.S. Pharmacopeia (USP)

    INCOG BioPharma Services

    Societal CDMO
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    CEO Spotlight: Salim Haffar

    The chief executive talks industry trends, challenges and what’s in store for PCI Pharma Services as it continues its rapid growth and global expansion strategy

    CEO Spotlight: Salim Haffar
    CEO Spotlight: Salim Haffar
    PCI Pharma Services' chief executive officer, Salim Haffar
    Tim Wright, Editor, Contract Pharma04.05.19
    PCI Pharma Services is an integrated full service contract manufacturing organization (CMO) capable of taking compounds from the earliest stages of development through to commercialization. Its core services support each stage of the product lifecycle, including drug development, clinical trial supply, commercial launch and ongoing commercial supply.

    Over the past decade, the Philadelphia-based CMO has undergone rapid growth of its services portfolio while expanding its global reach through acquisitions. In 2018, PCI bought Pharmaceutical Packaging Professionals (PPP) in Melbourne in March, providing new access to Australia and the wider Asia-Pacific region. Then in September it struck a deal for Sherpa Clinical Packaging in San Diego, CA, extending its presence across the U.S. to the West Coast and bolstering its presence in the biopharmaceutical development space.

    During the year, PCI also underwent some internal change when it announced in July that Salim Haffar would join the company as its new chief executive officer. He brings to the chief executive role more than 20 years of experience in the pharmaceutical industry. At the time of the announcement, he was serving as president of Aptar Pharma, where he oversaw the company’s growth strategy and journey to become a leading global provider of drug delivery systems across three end markets—prescription, consumer healthcare and injectables.

    He officially took hold of PCI’s reins in September, just as the Sherpa deal was going down. Contract Pharma had the chance to talk with Salim recently about the acquisition, PCI’s plans for the future and industry trends and challenges in general. 

    Contract Pharma (CP): You joined PCI just ahead of the Sherpa acquisition. Can you give some insight into that deal and how it expands PCI’s capabilities?

    Salim Haffar (SH):
    It started with a strategic goal to continue to grow and expand our clinical business on the West Coast where a lot of biopharma research and development activity is taking place. It really allows us to expand further into the early phases of drug development and expand our pipeline and better partner with our biopharma customers. The acquisition was the next logical step in our clinical services expansion strategy, further enhancing our development-stage capabilities and geographic presence. The addition of the San Diego business complements an amazing early phase business in Australia, bolstering a comprehensive offering for speed in initiating early phase studies for our clients. It broadens PCI’s strengths and provides a real depth of continuity for clients in a molecule-to-market portfolio of services.

    CP: When did PCI choose to focus more efforts on expanding the clinical side of its business?

    SH:
    PCI has really been focusing on expanding its clinical business for close to a decade now. First, by building the capability internally through our talent base and expanding our Rockford, IL facility. PCI’s also been on the acquisition trail for some time, buying companies like Biotec, which goes back to 2014. More recently, we acquired Dublin-based Millmount Healthcare, expanding PCI’s packaging capabilities in the EU. We then established an Asia-Pacific HQ and strengthened our position in the market with the acquisition of Melbourne, Australia-based Pharmaceutical Packaging Professionals (PPP). And, of course, Sherpa was the most recent piece of the puzzle to build our clinical business, enabling our expansion to the U.S. West Coast.

    CP: Earlier this year PCI unveiled a $20 million investment to expand its biotech technologies including advanced injectable delivery forms. What does this investment entail?

    SH:
    For years PCI has been at the forefront of packaging, testing and releasing branded biologic drug product. We now must also cater to a large customer base of biosimilars. The $20 million investment we are making is going to add expanded biotech clinical and commercial packaging and release testing capability at our Center of Excellence in Philadelphia. We will also expand cold chain capacity at numerous global sites to support our biotech infrastructure, both refrigerated as well as expand frozen and cryogenic temperatures. This latest investment will also include capacity expansion for cutting edge technologies for the labeling and assembly of state-of-the-art safety syringes, autoinjectors and pen devices with integrated high speed cartoning, and in-line serialization. This investment will help customers both in the clinical stage as well as the commercial stage. Leveraging this clinical-to-commercial expertise is a huge advantage for our clients, allowing us to best position them for success in development and commercialization.

    CP: What about investment in PCI’s legacy business?

    SH:
    In addition to the acquisitions we’ve discussed, PCI has undergone a lot of expansion in its existing legacy business. We are building a brand new dedicated and expanded clinical center in what I call our Mother Ship—the Rockford, IL site. We’re making this one of our largest clinical centers to serve a large customer base by adding 30,000 additional square feet of space in support of primary and secondary packaging and labeling operations for investigational medicinal products at the Clinical Services Center of Excellence.

    The expanded building, which is expected to open for business in late 2019 following internal fit-out and a period of validation and licensing, will provide increased flexibility to meet customer needs. Purpose-built for scalable primary and secondary packaging and labeling, the new packaging suites offer maximum flexibility, with the ability to operate on either a stand-alone or integrated basis across suites. The build will feature a state-of-the-art 2-8°C packaging room for cold chain products. Additionally, the expansion will include a reception area and will double the current office space to meet staff growth plans, demonstrating our commitment to investment in a leading position to support clients’ global clinical trial supply needs.

    The Rockford site is also undergoing a bottling line capacity expansion for commercial packaging. Construction of the additional packaging suites began in March 2018 to add considerable footprint for primary and secondary packaging operations equipped with high speed tablet filling, cartoning, as well as in-line serialization and aggregation. The new expansion will grow the bottling operation in Rockford by producing an extra 100 million bottles per year. Also worth noting, PCI is undertaking an significant expansion of the Rockford segregated potent compound packaging site, a stand-alone facility that supports these unique molecules, often in oncology, that require specialized high containment infrastructure and processes. This expansion furthers investment we have made in a complementary site in Dublin.

    CP: What are some other business highlights from the past 12 months?

    SH:
    We recently unveiled an investment in our infrastructure for packaging of controlled substances, complementing our capacity for blister packaging, a key tenet of recent calls for dispensing opioid prescriptions in limited quantity unit dose packaging as a tactic to combat substance misuse. We’ve extended onsite controlled substance storage at our commercial packaging locations in Philadelphia and Rockford and will undertake further expansions as demand increases for these specialized requirements. PCI supports DEA Schedule I-V controlled substances for both commercial prescription medicines, as well as those for investigational clinical trials, with approximately two million square feet of dedicated packaging infrastructure across the two locations.

    We’re also investing in adding clinical stage manufacturing capabilities at our Melbourne facility for injectable dose fill-finish. We are also investing heavily in our Dublin facility to support expansion across the base of clinical operations, in addition to commercial packaging and product release. There is a need to expand our European business driven by customer demand, but also to some degree in response to the Brexit situation. However, the greatest opportunity long term, is the expansion of our European footprint outside the UK.

    Moving forward PCI will continue to engage in good high levels investments, as well as modernize our facilities with the latest technological advancements. More importantly, we’re investing in talent too.

    CP: Speaking of technology, what are some of PCI’s most recent technological breakthroughs?

    SH:
    We’re introducing a lot of automation capabilities across our sites with the help of sophisticated, high-speed testing and manufacturing equipment. This includes advanced robotics, an exciting use of technology for which we see broad opportunity to pioneer new processes. We are also investing in high containment manufacturing for high potency drugs including environments for controlled substances or very high potent and/or sophisticated specialty pharma customers that require very special manufacturing environmental settings. The packaging locations we have invested in for both the U.S. (Rockford) and Europe (Dublin) are truly industry leading high containment solutions for our clients challenging molecules.

    CP: What are some of the crucial issues impacting pharma/biopharma manufacturing and supply and CDMOs in particular?

    SH:
    Pricing continues to be a major issue. For a number of years there existed a branded biologic drug base that was clearly highly differentiated, creating really great value to patients while addressing a large number of unmet medical needs, from autoimmune diseases to certain types of cancers. As the pressure on healthcare costs increases, as well as competition with the arrival of biosimilars, the challenge we face is how to reduce drug costs. Not just the manufacturing costs of the drug, but the whole ecosystem from drug development all the way through to manufacturing and commercialization. This is where the industry is facing its biggest challenge: the impact of increasing R&D and regulatory costs and the pressure that is putting on margins and prices.

    This is where strong partnerships with CDMOs are invaluable for pharma and biopharma. Customers want to see a track record and a high level of expertise that can serve as the foundation for a trusted partnership that can be sustained for many years.

    Customers come to us and really want us to become part of the solution to help them address problems they are facing. We are the experts in finding efficiencies, reducing costs, and also leveraging our own investments so they can invest their dollars into their own core expertise, such as research and development.

    So while the current pricing model, and how it cascades down the value chain, presents one big challenge affecting the whole industry, it’s also an opportunity for CDMOs to be part of the solution.

    CP: How will the product mix between small molecules and biologics unfold?

    SH:
    For the past 5-10 years a large portion of the drugs under development are biologics and biosimilars, which requires a different set of capabilities around drug development and API manufacturing, as well as providing clinical trial support, commercial packaging and release testing and so on, all the way through to distribution. It’s a whole new supply chain requiring different capabilities, changing the market needs and expectations versus older dosage forms like tablets and capsules and blistering. The growth trend of large molecules is not going to slow down, so it’s adding complexity in the supply chain.

    At the same time, small molecules are becoming more complex with the emergence of  highly potent and toxic drugs that require different manufacturing environments for specialty pharma firms. On the small molecule side we will continue to see the emergence of more complex dosage forms, particularly in oncology, a huge opportunity.

    Again, this is where CDMOs are coming in and providing solutions for their customers so they can focus on research and sales and marketing and not on having to build that sort of capability and capacity in house, creating a pathway for amazing new medicines to be delivered to patients around the world.

    CP: Lastly, how are partnerships in external development and manufacturing evolving, and what does the future hold?

    SH:
    Partnerships continue to evolve, but some are still around very basic principles. Having a high level of expertise and a proven track record that stands the test of time are the two fundamentals any pharma company, small or large, continues to look for when embarking on a partnership. Because, at the end of the day, a partnership is about trusting your drug product—whether it’s in the clinical, manufacturing or commercial stage—to a partner. So it’s a huge decision to make.

    A third factor important in a successful partnership is displaying pure transparency around your capabilities. A lot more pharma customers are looking to companies like PCI to partner on the basis of us providing them expanded capabilities. Whether it’s geographic presence or whether it’s particular expertise or capability or technology they would like to have. Not just for today, but for their future drug pipeline. They are depending on us and it is important for them to know we have the capabilities and will continue to add capabilities to support their efforts.

    As the regulatory rigor and the quality expectations continue to impact the pharma and biopharma industry moving forward, only those service providers who can demonstrate these basic fundamental skills will survive because the complexity of the industry is only going to increase. 
    Related Searches
    • supply chain
    • contract manufacturing organization
    • Filling
    • Clinical Packaging
    Suggested For You
    Legacy Pharma Solutions Legacy Pharma Solutions
    PCI Pharma Services PCI Pharma Services
    Asymchem Asymchem
    Catalent Pharma Solutions Catalent Pharma Solutions
    Regis Custom Pharma Regis Custom Pharma
    Softweb Solutions Softweb Solutions
    Vetio Animal Health Vetio Animal Health
    Adare Pharma Solutions Adare Pharma Solutions
    PCI Invests in High Potent Tableting and Powder Modification Capacity PCI Invests in High Potent Tableting and Powder Modification Capacity
    PCI Appoints CFO PCI Appoints CFO
    Industry 4.0 in the Pharma Industry Industry 4.0 in the Pharma Industry
    TraceLink Launches Smart Inventory Tracker TraceLink Launches Smart Inventory Tracker
    Pfenex and Alvogen Expand Development Collaboration Pfenex and Alvogen Expand Development Collaboration
    PCI Appoints CHRO PCI Appoints CHRO
    PCI Expands Controlled Substance Storage Capacity PCI Expands Controlled Substance Storage Capacity

    Related Buyers Guide Companies

    • Legacy Pharma Solutions

      Legacy Pharma Solutions

      ...
      Nathan Bender, Director, Sales & Marketing 12.07.21

    • Drug Development
      PCI Pharma Services

      PCI Pharma Services

      ...
      Tania Moorehead, Global Marketing Manager 10.20.21

    • Asymchem

      Asymchem

      ...
      Mandy Boyd, Asymchem 12.01.20


    • Drug Delivery
      Catalent Pharma Solutions

      Catalent Pharma Solutions

      ...
      Christopher, Director, Global Communications and Marketing 11.25.20

    • APIs | Clinical Trial Materials | Process Validation | QA/QC | Regulatory Affairs

      Regis Custom Pharma

      ...
      Deanna Rentner, Marketing Coordinator 11.12.20

    Loading, Please Wait..
    Trending
    • Aurigene Expands Biologics CDMO Capacity
    • Astellas To Transfer Manufacturing Plant To Delpharm
    • Catalent Adds New Cryogenic Capabilities At Japanese Facility
    • Thermo Fisher Expands Steriles Facility In Asia-Pacific Region
    • Lifecore Biomedical Enters Into $150M New Financing Deal
    Breaking News
    • Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility
    • JSR Life Sciences Consolidates KBI Biopharma and Selexis SA
    • Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    • Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies
    • Waters Corp. Acquires Light Scattering Company Wyatt Technology
    View Breaking News >
    CURRENT ISSUE

    May 2023

    • New Modalities Hog the Limelight
    • Cell and Gene Therapy is Coming of Age
    • Demand Surges for Cell and Gene Therapy Contract Manufacturing
    • Embracing a New Reality
    • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
    • Single-Use Technologies Enable Biologic Scaling
    • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    • FTEs in Drug Discovery
    • Digital Transformation in Pharma
    • What is a Manufacturing Ecosystem and Why are They Growing?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Verdure Sciences Receives Award for Sustainable, Ethical Turmeric Sourcing
    BGG Receives Patent for Saw Palmetto ID Method
    Premium Label & Packaging Solutions Receives Safe Quality Food (SQF) Certification
    Coatings World

    Latest Breaking News From Coatings World

    Brand Finance: Post-COVID Recovery Slows for Chemicals Industry Battling Energy Crisis
    BCF Calls for Greater Urgency on REACH Impasse
    MNYCA Hosts Afternoon Baseball Event
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CareDx, Miromatrix Collaborate on Bioengineered Organs Research
    Capitainer Releases to Market its Fully Automated Sample Handler
    Titan Medical Licenses Most IP to Intuitive; CEO Steps Down
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility
    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA
    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Stetson Introduces Men’s Grooming Portfolio
    Two Executives Depart from Unilever Amid CEO Transition
    L’Oréal Paris Welcomes Thuso Mbedu as Brand Ambassador
    Happi

    Latest Breaking News From Happi

    Beautycounter Appoints Board Director Mindy Mackenzie Interim CEO
    Unilever Ventures’ Backs Selva Ventures in $34 Million Fund for Early-Stage CPG Brands
    Two Executives Depart from Unilever Amid CEO Transition
    Ink World

    Latest Breaking News From Ink World

    ACTEGA, Makro Labelling to Advance Signite Technology
    BCF Requests Greater Urgency on REACH Impasse
    Updated Method Published for Entire BASF Product Portfolio
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    ACTEGA teams with Makro Labelling to advance Signite technology
    Constantia Flexibles and SB Packagings commence joint venture
    Inland donates new VersaStudio printer to local high school
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Mann+Hummel Names President Air Filtration Americas
    KNH Launches Eco-Friendly Menstrual Pads
    Niine Introduces India's First PLA-Based Sanitary Pads
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Enrollment Completed in Anika Therapeutics' Hyalofast Study
    Exactech Releases Next-Gen GPS Shoulder
    Data Shows Favorable Survivorship of MISHA Knee System & Reduction of Arthroplasty Risk in Patients
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    onsemi Presents Path to Accelerate Revenue Growth
    STMicroelectronics Introduces Waterproof MEMS Pressure Sensor
    Graphene Flagship to Join Euro Nano Forum 2023

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login